Gliomas are heterogeneous in the tumor immune microenvironment (TIM). However, a classification of gliomas based on immunogenomic profiling remains lacking. We hierarchically clustered gliomas based on the enrichment levels of 28 immune cells in the TIM in five datasets and obtained three clusters: immunity-high, immunity-medium, and immunity-low. Glioblastomas were mainly distributed in immunity-high and immunity-medium, while lower-grade gliomas were distributed in all the three subtypes and predominated in immunity-low. Immunity-low displayed a better survival than other subtypes, indicating a negative correlation between immune infiltration and survival prognosis in gliomas. IDH mutations had a negative correlation with glioma immunity. Immunity-high had higher tumor stemness and epithelial-mesenchymal transition scores and included more high-grade tumors than immunity-low, suggesting that elevated immunity is associated with tumor progression in gliomas. Immunity-high had higher tumor mutation burden and more frequent somatic copy number alterations, suggesting a positive association between tumor immunity and genomic instability in gliomas. The identification of immune-specific glioma subtypes has potential clinical implications for the immunotherapy of gliomas.

中文翻译：

---

基于免疫基因组学分析的胶质瘤免疫学分类

胶质瘤在肿瘤免疫微环境 (TIM) 中是异质的。然而，仍然缺乏基于免疫基因组学分析的神经胶质瘤分类。我们根据五个数据集中 TIM 中 28 个免疫细胞的富集水平对胶质瘤进行分层聚类，并获得三个聚类：免疫高、免疫中和免疫低。胶质母细胞瘤主要分布在免疫高和免疫中，而低级别胶质瘤则分布在所有三个亚型中，以免疫低为主。Immunity-low 显示出比其他亚型更好的存活率，表明免疫浸润与胶质瘤存活预后之间呈负相关。IDH突变与胶质瘤免疫呈负相关。高免疫具有更高的肿瘤干性和上皮-间质转化评分，并且比低免疫具有更多的高级别肿瘤，这表明免疫升高与胶质瘤的肿瘤进展有关。高免疫具有更高的肿瘤突变负荷和更频繁的体细胞拷贝数改变，表明肿瘤免疫与胶质瘤基因组不稳定性之间存在正相关。免疫特异性神经胶质瘤亚型的鉴定对神经胶质瘤的免疫治疗具有潜在的临床意义。